Chromocell announces amendment to stock repurchase plan

Freehold, n.j., oct. 24, 2024 (globe newswire) -- chromocell therapeutics corporation (“chromocell”, or the “company”), (nyse american: chro), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “board of directors”) has authorized an amendment (the “amendment”) to the company's existing stock repurchase plan (as amended, the “repurchase plan”) to increase the total value of shares of chromocell's common stock (“common stock”) available for repurchase by the company under the repurchase plan by an additional $500,000, to $750,000.
CHRO Ratings Summary
CHRO Quant Ranking